Current position:News > News > Insights
ROR1:Merck Sharp & Dohme Initiates Phase III Clinical Trial of ROR1 ADC
吉满生物
2024-12-06

On Dec. 5, according to the clinical trials website, Merck Sharp & Dohme registered a study titled “A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)”. in Participants With Previously Untreated DLBCL (MK-2140-010)” (waveLINE-010).


图片


The study will start in December 2025 with a planned enrollment of 1,046 cases.The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.


图片


Overexpression of receptor tyrosine kinase-like orphan receptor 1 (ROR1) contributes to cancer cell proliferation, survival and migration, playing crucial roles in tumor development. ROR1 has been proposed as a potential therapeutic target for cancer treatment. Learn more about our ROR1 catalog.



Latest news
Insights
2025-11-05
Accelerating Development of FOLR1 Target to Advance Multidimensional Cancer Therapy
Folate receptor alpha (FRα, FOLR1) is rapidly becoming one of the hottest targets in tumor therapy. With multiple antibody–drug conjugates (ADCs) now entering Phase III trials from global leaders like Eli Lilly and AstraZeneca, and emerging players such as Bio Thera and ProTarget Bio joining the race, competition around this target is intensifying.

From Elahere’s FDA approval to a new generation of FRα-directed ADCs, monoclonal antibodies, CAR-T therapies, and vaccines, the field is shifting from concept validation to clinical reality.

Dive into the full analysis to see how FRα is redefining the landscape of epithelial tumor treatment — and why it’s drawing worldwide attention from oncology innovators.
Insights
2025-10-31
PD-1 × IL-2: A Combined Approach to Redefining Tumor Immunotherapy Strategies
While PD-1 inhibitors have transformed cancer treatment, their limits are becoming clear — and a new wave of innovation is rising. Cytokine engineering and PD-1 × IL-2 fusion therapies are redefining how we think about precision immune activation.

As PD-1 inhibitors reach their limits, the next frontier lies in cytokine engineering. Both Roche and Innovent Biologics are pursuing the PD-1 × IL-2v fusion strategy — yet with fundamentally different design philosophies.
Insights
2025-10-23
TSHR: The Core Target in Thyroid Metabolic Regulation and Disease Therapy
The thyroid-stimulating hormone receptor (TSHR) is emerging as a key target in next-generation thyroid and autoimmune disease treatments. Once limited to hormone regulation, TSHR therapies now combine endocrine and immune pathways for greater precision and efficacy. With growing research and industry momentum, TSHR is shaping the future of smarter, more targeted thyroid therapies.
Current position:News > News > Insights
classify
ROR1:Merck Sharp & Dohme Initiates Phase III Clinical Trial of ROR1 ADC
吉满生物
2024-12-06

On Dec. 5, according to the clinical trials website, Merck Sharp & Dohme registered a study titled “A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)”. in Participants With Previously Untreated DLBCL (MK-2140-010)” (waveLINE-010).


图片


The study will start in December 2025 with a planned enrollment of 1,046 cases.The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.


图片


Overexpression of receptor tyrosine kinase-like orphan receptor 1 (ROR1) contributes to cancer cell proliferation, survival and migration, playing crucial roles in tumor development. ROR1 has been proposed as a potential therapeutic target for cancer treatment. Learn more about our ROR1 catalog.



Message consultation
reset
submit
Message
Message consultation
reset
submit